Eyeworld

EW MEETING REPORTER 62 May 2011 "perils of the pupil," said R. Doyle Stulting, M.D., Woolfson Eye Insti- tute, Atlanta, include the fact that the axis of the best-fit ellipse changes with lighting. 8. Monovision can reduce con- trast sensitivity and stereoacuity and cause asthenopia through binocular rivalry; however, said Graham Barrett, M.D., president, APACRS, limiting myopic defocus to 1.5 D avoids these problems. Other issues affecting patient satisfaction are eas- ily dealt with; managing expecta- tions and prioritizing distance vision generally helps. 9. NuLens (Herzliya Pituach, Israel) uses the mechanics of the col- lapsed capsular bag to provide ac- commodation, said Jorge Alio, M.D., Miguel Hernandez University, Alicante, Spain. A 100-micron varia- tion achieves about 7 D of accom- modation. In his experience, the NuLens can restore functional vision to legally blind patients. 10. Okihiro Nishi, M.D., and his colleagues at Nishi Eye Hospital, Osaka, Japan, have developed an ac- commodating membrane IOL. Two artificial membranes seal the ante- rior and posterior capsulorhexis to contain silicone liquid injected into the bag. Implantation takes 20-30 minutes; the anterior and posterior rhexes circumvent capsular opacifi- cation. 11. The restoration of accommo- dation using a femtosecond laser to "soften" the hardened presbyopic lens is theoretically possible, said Ronald Krueger, M.D., Cole Eye In- stitute, Cleveland Clinic. However, he and his colleagues have yet to prove it, having performed the pro- cedure in 16 patients so far. 12. The "best candidate" for managing presbyopia, said Glauco Reggiani Mello, M.D., Cole Eye In- stitute, is manipulation of spherical aberration to expand depth of focus; however, the ideal magnitude of aberration is unknown. The solution may be to customize treatment using an adaptive optics visual simu- lator. Editors' note: Dr. Alio has a financial interest in NuLens. Dr. Barrett has fi- nancial interests in Bausch & Lomb (Rochester, N.Y.) and Hoya (Santa Clara, Calif.). Dr. Carrizzo has no fi- nancial interests related to his topic. Dr. Findl has financial interests in several ophthalmic companies, including Ab- bott Medical Optics (Santa Ana, Calif.) and Alcon (Fort Worth, Texas). Dr. Izquierdo has financial interests in NeoVista (Newark, Calif.) and NuLens. Dr. Krueger has a financial interest in LensAR (Winter Park, Fla.). Dr. Mello has no financial interests related to his topic. Dr. Nishi helped develop the bag filling accommodative membrane IOL he described. Dr. Reinstein has a finan- cial interest in Carl Zeiss Meditec (Dublin, Calif.). Dr. Steinert has a fi- nancial interest in ReVision Optics. Dr. Stulting has a financial interest in Calhoun Vision. Dr. Yeoh has a finan- cial interest in Alcon. Innovators Session highlights advances in technology With more than 800 papers submit- ted on "widely ranging topics," Roger F. Steinert, M.D., Irving H. Leopold professor, ophthalmology chair, director, Gavin Herbert Eye In- stitute, University of California, Irvine, culled what he called the best of the best to be presented at this year's Innovators Session. Among the topics was using rat models to determine the effect of intraocularly administered photoactive quantum dots in progressive photoreceptor degeneration. Jeffrey L. Olson, M.D., associate professor, ophthal- mology department, University of Colorado, Denver, said both control and sham surgery groups demon- strated a progressive decline in the amplitude of the ERG recordings over the 6 weeks post-procedure. Ekkehard Fabian, M.D., Rosen- heim, Germany, spoke about a new duo linear foot pedal function to op- timize phaco technique. Using a duo linear foot pedal helps to adopt set- tings on the fly to specific situations during lens removal surgery, he said. Focused femtosecond laser pulses can increase the refractive index of lens material by about 0.01, said Josef F. Bille, M.D., University of Heidelberg, Germany. "All cataract surgery results in consider- able refractive errors," he said. By personalizing and customizing the IOL pre-op, physicians can adjust the IOL power based on the individ- ual patient. As clinicians continue to learn more about the ocular surface, how to better treat and diagnose issues with the surface is taking center stage, and new screening devices are helping. Herb Kaufman, M.D., pro- Reporting live from the 2011 ASCRS•ASOA Symposium and Congress, San Diego, Calif. Editors' note: This Meeting Reporter contains original reporting by the EyeWorld news team.

• Cover